Stoke Therapeutics, Inc. (STOK) — closed signal from October 1, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 30, 2025.
Predicted vs. what happened
What happened
Reached its target in 13 days.
The thesis — published October 1, 2025
Stoke looks like a fast-moving biotech whose price has fallen too far and may bounce. Fresh results with Biogen for its Dravet treatment help keep interest high. The recent average price is starting to turn up, and investor mood is strong. Over the next 0-3 months, the plan is to buy in stages and add only if the move upward is confirmed, while keeping position size modest because the stock can swing a lot.
Primary drivers
- Recent study with Biogen showed encouraging results for Dravet patients
- Price looks washed out, and the recent average price is turning up
- Investor mood is strong, and the company's core science looks credible
- Shares move fast, which can suit a disciplined short-term trade plan
How it played out
STOK: target reached in 13 days
Lyra published STOK on 2025-10-01 at $23.47 with expected growth of 40%. The thesis pointed to encouraging Dravet study results with Biogen, a washed-out price, a recent average price that was turning up, strong investor mood, credible core science, and a short-term setup where fast share moves could fit a disciplined trade plan.
Inside the window, STOK reached a peak of $38.69 on 2025-10-16. That was above the $32.86 target, and the target was reached in 13 days. The peak gain was 64.9%. By 2025-12-30, the stock ended at $31.82. The thesis played out.
What happened during the window
On 2025-11-04, Stoke reported third-quarter 2025 results. On 2025-12-16, Investor's Business Daily reported that the Biogen collaboration helped drive revenue growth in that quarter.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.